Antibody-drug conjugates: the new frontier of chemotherapy
S Ponziani, G Di Vittorio, G Pitari, AM Cimini… - International Journal of …, 2020 - mdpi.com
In recent years, antibody-drug conjugates (ADCs) have become promising antitumor agents
to be used as one of the tools in personalized cancer medicine. ADCs are comprised of a …
to be used as one of the tools in personalized cancer medicine. ADCs are comprised of a …
HER3 in cancer: from the bench to the bedside
L Gandullo-Sánchez, A Ocaña, A Pandiella - Journal of Experimental & …, 2022 - Springer
The HER3 protein, that belongs to the ErbB/HER receptor tyrosine kinase (RTK) family, is
expressed in several types of tumors. That fact, together with the role of HER3 in promoting …
expressed in several types of tumors. That fact, together with the role of HER3 in promoting …
Thirty years of HER3: from basic biology to therapeutic interventions
HM Haikala, PA Jänne - Clinical Cancer Research, 2021 - AACR
HER3 is a pseudokinase member of the EGFR family having a role in both tumor
progression and drug resistance. Although HER3 was discovered more than 30 years ago …
progression and drug resistance. Although HER3 was discovered more than 30 years ago …
[HTML][HTML] HER3 signaling and targeted therapy in cancer
ERBB family members including epidermal growth factor receptor (EGFR) also known as
HER1, ERBB2/HER2/Neu, ERBB3/HER3 and ERBB4/HER4 are aberrantly activated in …
HER1, ERBB2/HER2/Neu, ERBB3/HER3 and ERBB4/HER4 are aberrantly activated in …
[HTML][HTML] Understanding the biology of HER3 receptor as a therapeutic target in human cancer
HER3 belongs to the human epidermal growth factor receptor (HER) family which also
includes HER1/EGFR/erbB1, HER2/erbB2, and HER4/erbB4. As a unique member of the …
includes HER1/EGFR/erbB1, HER2/erbB2, and HER4/erbB4. As a unique member of the …
Targeting of erbB3 receptor to overcome resistance in cancer treatment
The erbB receptors, including the epidermal growth factor receptor (EGFR), erbB2 (also
known as HER2/neu), erbB3 (or HER3), and erbB4 (or HER4), are often aberrantly activated …
known as HER2/neu), erbB3 (or HER3), and erbB4 (or HER4), are often aberrantly activated …
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans
Over the past decade, immunotherapy delivered novel treatments for many cancer types.
However, lung cancer still leads cancer mortality, and non-small-cell lung carcinoma …
However, lung cancer still leads cancer mortality, and non-small-cell lung carcinoma …
[HTML][HTML] A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer
JM Mota, KA Collier, RLB Costa, T Taxter, A Kalyan… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Heregulins (HRGs) bind to the receptors HER3 or HER4, induce receptor dimerization, and
trigger downstream signaling that leads to tumor progression and resistance to targeted …
trigger downstream signaling that leads to tumor progression and resistance to targeted …
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target
E Capone, T Tryggvason, I Cela, B Dufrusine… - Cell Death …, 2023 - nature.com
HER-3 (also known as ErbB-3) is a human epidermal growth factor receptor tyrosine kinases
family member, and its expression in CRC (colorectal cancer) tissues was previously …
family member, and its expression in CRC (colorectal cancer) tissues was previously …
Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3
N Gaborit, M Lindzen, Y Yarden - Human vaccines & …, 2016 - Taylor & Francis
Cancer progression depends on stepwise accumulation of oncogenic mutations and a
select group of growth factors essential for tumor growth, metastasis and angiogenesis …
select group of growth factors essential for tumor growth, metastasis and angiogenesis …